ERBB2 and breast carcinoma: In a Dutch randomized, multicenter, placebo-controlled, double-blind clinical trial, Boekhout et al45 included 210 patients with HER2-positive early breast cancer considered for adjuvant treatment with anthracycline-containing chemotherapy who were randomized to candesartan vs placebo.